Home Featured

Featured

Random

Mindset Pharma Announces Publication of Three PCT Patent Applications for Its Next Generation Psychedelic Drug Candidates

Optimi Health Completes Pre-Clinical Trial Application Meeting

The Obscure Advisory Panel Blocking Dozens of Psychedelic Studies in California

atai Life Sciences Reports Second Quarter 2021 Financial Results and Business Update

Clearmind Medicine Closes US$3.5 Million Public Offering

Psychedelic Education: Insights, Advice, and Where to Start

Psyence Group Announces Collaboration with the Scientific Research Council (SRC) of...

COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in...

PT298 – Michael Sapiro, PsyD – Vital Psychedelic Conversations

Horizons ETFs Rebalances World’s First Psychedelics ETF

The Psychedelic Mind: How Neuroscience Can Help You Navigate Your Inner...

PT363 – Reggie Harris – Cannabis and Psilocybin: The Complications of...

Navigating Colorado’s Regulated Psychedelic Model: Lessons From the Front Lines

Psychedelic Bulletin: MDMA Fast-Tracked in UK; FDA Clears MindMed LSD Trial;...

The Wild World of 19th Century Psychedelics

12 3...316 Page 1 of 316

EDITOR PICKS

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical,...

Bit Yaden on Preparing the Next Generation of Psychiatrists for a...

“If I can’t change my views based on evidence, then why...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.